Anteris Technologies Global Corp.

# Signal Note: Perceptive Advisors Initiates AVR Position Perceptive's $8.4M entry into Anteris suggests conviction in the company's valve replacement pipeline, likely driven by upcoming clinical catalysts for its proprietary aortic valve technology designed to address durability limitations in current prosthetics. Edelman's track record backing clinical-stage assets indicates potential visibility into near-term data readouts or regulatory pathway progress that de-risks the program. Key catalyst watch: Phase II/III trial results and FDA feedback on the valve's long-term performance claims.